Ledipasvir (formerly GS-5885) is a drug for the treatment of hepatitis C that was developed by Gilead Sciences.[1] After completing Phase III clinical trials, on February 10, 2014 Gilead filed for U.S. approval of a ledipasvir/sofosbuvir fixed-dose combination tablet for genotype 1 hepatitis C.[2][3] The ledipasvir/sofosbuvir combination is a direct-acting antiviral agent that interferes with HCV replication and can be used to treat patients with genotypes 1a or 1b without PEG-interferon or ribavirin.
Ledipasvir is an inhibitor of the hepatitis C virus NS5A protein.
Introduction:
Product Description
CAS NO.: 1256388-51-8
MF: C49H54F2N8O6
Appearance: White or white crystalline powderpetroleum ether.
Specification:99%min
Standard: EP/BP/USP
Odor: odorless
Analysis Certificate
Specification:
| Item | Specifications |
| Apperance | white or almost white powder |
| Purity(HPLC) | ≥99 % |
| Any impurity | ≤0.2% |
| Total impurities | ≤0.5% |
| Loss on drying | ≤1.0% |
| Residue on ignition | ≤0.1% |
| Heavy metal | ≤10ppm |
Packaging & Shipping
Packing:25kg/drum or as your request.
Storage Situation: Stored in a cool and dry well-closed container. Keep away from moisture and strong light/heat.
Sour company's websitehelf Life: Two years when properly stored.
Delivery: within two weeks after receiving your prepayment.
没有评论:
发表评论